Can a patient receiving chronic dialysis safely take Imdur (isosorbide mononitrate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Dialysis Patients Take Imdur?

Yes, dialysis patients can safely take Imdur (isosorbide mononitrate), and it should be used according to general population guidelines for coronary artery disease management, with specific attention to timing relative to dialysis sessions to avoid hypotension. 1

Guideline-Based Recommendation

The K/DOQI cardiovascular guidelines explicitly state that dialysis patients with chronic coronary artery disease should receive nitroglycerin (which includes nitrate preparations like isosorbide mononitrate) following the same indications as the general population 1. This represents a Level C recommendation from authoritative nephrology guidelines.

Critical Timing Considerations

The most important caveat is avoiding nitrate administration during low preload states. Specifically:

  • Do NOT dose nitrates at the end of hemodialysis sessions when patients are hypovolemic from ultrafiltration 1
  • Consider nocturnal dosing to avoid interference with dialysis delivery 1
  • Modify dosing regimens so cardiovascular medications don't adversely impact ultrafiltration 1

The rationale is straightforward: nitrates cause vasodilation and reduce preload. When combined with the hypovolemia that occurs during/after hemodialysis, this can precipitate severe hypotensive episodes 1.

Pharmacokinetic Profile in Dialysis

Isosorbide mononitrate has favorable characteristics for dialysis patients:

  • Virtually 100% bioavailable with no significant first-pass metabolism 2
  • Minimal dialytic removal: Only about 0.5% of the administered dose is removed during a 5-hour hemodialysis session 3
  • No dose adjustment required for renal failure - the pharmacokinetic profile is unchanged in patients with renal failure 2
  • Negligible loss during peritoneal dialysis 3

Clinical Evidence in Dialysis Populations

A prospective randomized trial specifically in maintenance hemodialysis patients demonstrated that sustained-release isosorbide mononitrate (30-120 mg daily) was safe and effective for:

  • Blood pressure control
  • Reduction in left ventricular mass index
  • Decreased incidence of acute left heart failure (1.4% vs 11.1% in controls) 4

The adverse event rate was only 1.4%, confirming excellent tolerability 4.

More recent data on the related compound hydralazine-isosorbide dinitrate in dialysis patients with heart failure showed improved cardiovascular outcomes, including reduced all-cause mortality (HR 0.48) and cardiovascular death (HR 0.62) 5.

Practical Dosing Algorithm

  1. Start with standard doses - no renal adjustment needed (e.g., Imdur 30-60 mg once daily)
  2. Time administration in the morning or at night - specifically avoid dosing within 4-6 hours before dialysis
  3. Assess volume status before each dose during the first week
  4. Monitor for headache (most common side effect, usually mild and improves with continued therapy) 6
  5. Titrate based on clinical response, not renal function

Common Pitfalls to Avoid

  • Withholding nitrates unnecessarily due to concerns about renal failure - the drug is safe in this population
  • Dosing immediately before or during dialysis - this is when hypotension risk is highest
  • Assuming dose reduction is needed - isosorbide mononitrate clearance is not significantly affected by renal failure 2
  • Discontinuing abruptly - this may exacerbate anginal symptoms 6

Monitoring Parameters

  • Blood pressure before and after dialysis sessions
  • Symptoms of hypotension (dizziness, lightheadedness)
  • Headache severity (usually improves after first week)
  • Anginal symptoms and exercise tolerance

The bottom line: Imdur is both safe and indicated for dialysis patients with coronary artery disease, provided you avoid dosing during periods of intradialytic or post-dialytic hypovolemia.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.